Zobrazeno 1 - 10
of 420
pro vyhledávání: '"Ru Ma"'
Publikováno v:
Cancer Biology & Medicine, Vol 21, Iss 7, Pp 586-605 (2024)
Pseudomyxoma peritonei (PMP) is an indolent malignant syndrome. The standard treatment for PMP is cytoreductive surgery combined with intraperitoneal hyperthermic chemotherapy (CRS + HIPEC). However, the high recurrence rate and latent clinical sympt
Externí odkaz:
https://doaj.org/article/f2cf9c123c7b449ea09c12dc34328c51
Autor:
Jun-lin Lv, Yu-jun Tan, Yu-shan Ren, Ru Ma, Xiao Wang, Shu-yan Wang, Wan-qing Liu, Qiu-sheng Zheng, Jing-chun Yao, Jun Tian, Jie Li
Publikováno v:
Journal of Advanced Research, Vol 60, Iss , Pp 215-231 (2024)
Introduction: Although colon (COAD) and rectal adenocarcinoma (READ) combined to refer to colorectal cancer (CRC), substantial clinical evidence urged that CRC should be treated as two different cancers due to compared with READ, COAD showed higher m
Externí odkaz:
https://doaj.org/article/e5b72feb6bf944ed8d6c66713ebc6399
Publikováno v:
World Journal of Surgical Oncology, Vol 22, Iss 1, Pp 1-9 (2024)
Abstract Background Malignant peritoneal mesothelioma (MPM) is a rare and highly aggressive tumor. Its clinical manifestations are diverse, and the symptoms are not specific. Some patients will develop paraneoplastic syndrome (PS) during the disease
Externí odkaz:
https://doaj.org/article/09676f305c7b4138b9c9d2edef04b02a
Publikováno v:
Cancer Medicine, Vol 13, Iss 6, Pp n/a-n/a (2024)
Abstract Background Pseudomyxoma peritonei (PMP) is a rare clinical malignant syndrome, and its rarity causes a lack of pathology research. This study aims to quantitatively analyze HE‐stained pathological images (PIs), and develop a new predictive
Externí odkaz:
https://doaj.org/article/431f8eaa25d24124a79e5c746a4c0e04
Publikováno v:
World Journal of Surgical Oncology, Vol 21, Iss 1, Pp 1-7 (2023)
Abstract Background As the standard treatment for pseudomyxoma peritonei (PMP), cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) can significantly prolong the survival of PMP patients, and some patients can even achi
Externí odkaz:
https://doaj.org/article/2a65d75ddf934746b04d9c726a7e8071
Autor:
Rui Yang, Xin Zhao, Yu-Bin Fu, Yu-Lin Lin, Ru Ma, Yan-Dong Su, He-Liang Wu, Xin-Li Liang, Yan Li
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Background Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) is the standard treatment for pseudomyxoma peritonei (PMP). It can significantly prolong the survival of patients, but at the same time may increas
Externí odkaz:
https://doaj.org/article/dcc7a53784b14f75a79216e63f9163f3
Autor:
Yan-Dong Su, Xin Zhao, Ru Ma, Yu-Bin Fu, Zhi-Ran Yang, He-Liang Wu, Yang Yu, Rui Yang, Xin-li Liang, Xue-Mei Du, Yue Chen, Yan Li
Publikováno v:
International Journal of Hyperthermia, Vol 40, Iss 1 (2023)
AbstractObjectives To establish a Bayesian network (BN) model to predict the survival of patients with malignant peritoneal mesothelioma (MPM) treated with cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC).Methods The
Externí odkaz:
https://doaj.org/article/ee5273a47ed44db881e8113ca266a6d6
Autor:
Rui Yang, Yan-Dong Su, Gang Liu, Yang Yu, Xin-Bao Li, Xin Zhao, Zhong-He Ji, Ru Ma, Zhi-Ran Yang, Yu-Lin Lin, He-Liang Wu, Yan Li
Publikováno v:
International Journal of Hyperthermia, Vol 40, Iss 1 (2023)
AbstractObjective To investigate the effects of standardized fluid management (SFM) on cardiac function in patients with pseudomyxoma peritonei (PMP) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).Method Patie
Externí odkaz:
https://doaj.org/article/81ab9f71a807413c98d7578f87408b1b
Autor:
Rihan Wu, Ru Ma, Xiaojun Duan, Jiandong Zhang, Kexin Li, Lei Yu, Mingyang Zhang, Pengxia Liu, Changshan Wang
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionLung squamous cell carcinoma (LUSC) is a unique subform of nonsmall cell lung cancer (NSCLC). The lack of specific driver genes as therapeutic targets leads to worse prognoses in patients with LUSC, even with chemotherapy, radiotherapy, o
Externí odkaz:
https://doaj.org/article/54772d165d8a42a1808ab74c95cbbdfe
Publikováno v:
Cancer Medicine, Vol 12, Iss 3, Pp 2637-2645 (2023)
Abstract Objectives To establish a survival prognostic model for pseudomyxoma peritonei (PMP) treated with cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) based on Bayesian network (BN). Methods 453 PMP patients wer
Externí odkaz:
https://doaj.org/article/1cb96e3fb90946efb3ef88c93a142582